Vor Biopharma (VOR) Cash from Financing Activities (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Cash from Financing Activities data on file, last reported at $74.9 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $74.9 million, up 12454.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $579.3 million (up 999.42% YoY), and the FY2025 annual result was $503.8 million, up 843.6% from the prior year.
• Cash from Financing Activities slipped to $74.9 million in Q1 2026 per VOR's latest filing, from $307.8 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $307.8 million in Q4 2025 and troughed at -$606000.0 in Q1 2025.
• A 5-year average of $44.2 million and a median of $604000.0 in 2022 frame the typical range for Cash from Financing Activities.
• On a YoY basis, Cash from Financing Activities climbed as much as 564825.81% in 2025 and fell as far as 731.25% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $112.3 million in 2022, then slumped by 99.98% to $25000.0 in 2023, then jumped by 213044.0% to $53.3 million in 2024, then soared by 477.64% to $307.8 million in 2025, then sank by 75.68% to $74.9 million in 2026.
• Business Quant data shows VOR's Cash from Financing Activities at $74.9 million in Q1 2026, $307.8 million in Q4 2025, and $21.5 million in Q3 2025.